Kidney Transplantation in Cirrhotic Patients



Cirrhotic patients with concurrent end-stage renal disease pose a unique challenge in their management. In many cases, a combined liver and kidney transplantation is performed but there is a significant amount of cases where cirrhosis is well compensated and the patient does not have a straightforward indication for liver transplantation. Kidney transplantation alone could take these patients off dialysis; however, there is the danger of liver decompensation and subsequent mortality, as in any other major surgery performed in cirrhotics. Many centers deny kidney transplantation in cirrhotics, but there are data to support that if planed carefully with appropriate selection of donors and recipients, kidney transplantation alone in certain cirrhotic patients is indicated and appropriate.


Kidney transplantation Cirrhosis Portal hypertension 


  1. 1.
    Chan EY, Bhattacharya R, Eswaran S, et al. Outcomes after combined liver-kidney transplant vs. kidney transplant followed by liver transplant. Clin Transpl. 2015;29(1):60–6. doi: 10.1111/ctr.12484.CrossRefGoogle Scholar
  2. 2.
    Parsikia A, Campos S, Khanmoradi K, et al. Equal 3-year outcomes for kidney transplantation alone in HCV-positive patients with cirrhosis. Int Surg. 2015;100(1):142–54. doi: 10.9738/INTSURG-D-13-00231.1.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Morales JM, Fabrizi F. Hepatitis C and its impact on renal transplantation. Nat Rev Nephrol. 2015;11(3):172–82. doi: 10.1038/nrneph.2015.5.CrossRefPubMedGoogle Scholar
  4. 4.
    Chan TM, Lok AS, Cheng IK, Chan RT. Prevalence of hepatitis C virus infection in hemodialysis patients: a longitudinal study comparing the results of RNA and antibody assays. Hepatology. 1993;17(1):5–8. 0270-9139(93)90183-N [pii].CrossRefPubMedGoogle Scholar
  5. 5.
    Finelli L, Miller JT, Tokars JI, Alter MJ, Arduino MJ. National surveillance of dialysis-associated diseases in the United States, 2002. Semin Dial. 2005;18(1):52–61. SDI18108 [pii].CrossRefPubMedGoogle Scholar
  6. 6.
    Fissell RB, Bragg-Gresham JL, Woods JD, et al. Patterns of hepatitis C prevalence and seroconversion in hemodialysis units from three continents: The DOPPS. Kidney Int. 2004;65(6):2335–42. doi: 10.1111/j.1523-1755.2004.00649.x.CrossRefPubMedGoogle Scholar
  7. 7.
    Jadoul M, Poignet JL, Geddes C, et al. The changing epidemiology of hepatitis C virus (HCV) infection in haemodialysis: European multicentre study. Nephrol Dial Transplant. 2004;19(4):904–9. doi: 10.1093/ndt/gfh012.CrossRefPubMedGoogle Scholar
  8. 8.
    Pereira BJ, Levey AS. Hepatitis C virus infection in dialysis and renal transplantation. Kidney Int. 1997;51(4):981–99.CrossRefPubMedGoogle Scholar
  9. 9.
    Covic A, Iancu L, Apetrei C, et al. Hepatitis virus infection in haemodialysis patients from moldavia. Nephrol Dial Transplant. 1999;14(1):40–5.CrossRefPubMedGoogle Scholar
  10. 10.
    Hmaied F, Ben Mamou M, Saune-Sandres K, et al. Hepatitis C virus infection among dialysis patients in Tunisia: incidence and molecular evidence for nosocomial transmission. J Med Virol. 2006;78(2):185–91. doi: 10.1002/jmv.20526.CrossRefPubMedGoogle Scholar
  11. 11.
    Saxena AK, Panhotra BR. The impact of nurse understaffing on the transmission of hepatitis C virus in a hospital-based hemodialysis unit. Med Princ Pract. 2004;13(3):129–35. doi: 10.1159/000076951.CrossRefPubMedGoogle Scholar
  12. 12.
    Morales JM, Campistol JM, Dominguez-Gil B. Hepatitis C virus infection and kidney transplantation. Semin Nephrol. 2002;22(4):365–74. S0270929502500474 [pii].PubMedGoogle Scholar
  13. 13.
    Musso G, Gambino R, Tabibian JH, et al. Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis. PLoS Med. 2014;11(7):e1001680. doi: 10.1371/journal.pmed.1001680.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Musso G, Gambino R, Cassader M, Pagano G. Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann Med. 2011;43(8):617–49. doi: 10.3109/07853890.2010.518623.CrossRefPubMedGoogle Scholar
  15. 15.
    Fabrizi F, Poordad FF, Martin P. Hepatitis C infection and the patient with end-stage renal disease. Hepatology. 2002;36(1):3–10. S0270913902000009 [pii].CrossRefPubMedGoogle Scholar
  16. 16.
    Patel V, Marsano L, Eng M. Decompensated cirrhosis after renal transplantation: a case report. Case Rep Transplant. 2011;2011:862567. doi: 10.1155/2011/862567.PubMedPubMedCentralGoogle Scholar
  17. 17.
    Berthoux F. Hepatitis C virus infection and disease in renal transplantation. Nephron. 1995;71(4):386–94.CrossRefPubMedGoogle Scholar
  18. 18.
    Glicklich D, Thung SN, Kapoian T, Tellis V, Reinus JF. Comparison of clinical features and liver histology in hepatitis C-positive dialysis patients and renal transplant recipients. Am J Gastroenterol. 1999;94(1):159–63. S0002927098006698 [pii].CrossRefPubMedGoogle Scholar
  19. 19.
    Perez RM, Ferreira AS, Medina-Pestana JO, et al. Is hepatitis C more aggressive in renal transplant patients than in patients with end-stage renal disease? J Clin Gastroenterol. 2006;40(5):444–8. 00004836-200605000-00016 [pii].CrossRefPubMedGoogle Scholar
  20. 20.
    Hanafusa T, Ichikawa Y, Kishikawa H, et al. Retrospective study on the impact of hepatitis C virus infection on kidney transplant patients over 20 years. Transplantation. 1998;66(4):471–6.CrossRefPubMedGoogle Scholar
  21. 21.
    Izopet J, Rostaing L, Sandres K, et al. Longitudinal analysis of hepatitis C virus replication and liver fibrosis progression in renal transplant recipients. J Infect Dis. 2000;181(3):852–8. JID991149 [pii].CrossRefPubMedGoogle Scholar
  22. 22.
    Rao KV, Anderson WR, Kasiske BL, Dahl DC. Value of liver biopsy in the evaluation and management of chronic liver disease in renal transplant recipients. Am J Med. 1993;94(3):241–50. 0002-9343(93)90055-T [pii].CrossRefPubMedGoogle Scholar
  23. 23.
    de Oliveira Uehara SN, Emori CT, da Silva Fucuta Pereira P, et al. Histological evolution of hepatitis C virus infection after renal transplantation. Clin Transpl. 2012;26(6):842–8. doi: 10.1111/j.1399-0012.2012.01635.x.CrossRefGoogle Scholar
  24. 24.
    Maluf DG, Fisher RA, King AL, et al. Hepatitis C virus infection and kidney transplantation: predictors of patient and graft survival. Transplantation. 2007;83(7):853–7. doi: 10.1097/ Scholar
  25. 25.
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Dulai G. Hepatitis C virus antibody status and survival after renal transplantation: meta-analysis of observational studies. Am J Transplant. 2005;5(6):1452–61. AJT864 [pii].CrossRefPubMedGoogle Scholar
  26. 26.
    Rostami Z, Nourbala MH, Alavian SM, Bieraghdar F, Jahani Y, Einollahi B. The impact of hepatitis C virus infection on kidney transplantation outcomes: a systematic review of 18 observational studies: the impact of HCV on renal transplantation. Hepat Mon. 2011;11(4):247–54.PubMedPubMedCentralGoogle Scholar
  27. 27.
    Cruzado JM, Bestard O, Grinyo JM. Impact of extrahepatic complications (diabetes and glomerulonephritis) associated with hepatitis C virus infection after renal transplantation. Contrib Nephrol. 2012;176:108–16. doi: 10.1159/000332389.CrossRefPubMedGoogle Scholar
  28. 28.
    Corell A, Morales JM, Mandrono A, et al. Immunosuppression induced by hepatitis C virus infection reduces acute renal-transplant rejection. Lancet. 1995;346(8988):1497–8. S0140-6736(95)92520-1 [pii].CrossRefPubMedGoogle Scholar
  29. 29.
    Wolfe RA, Ashby VB, Milford EL, et al. Comparison of mortality in all patients on dialysis, patients on dialysis awaiting transplantation, and recipients of a first cadaveric transplant. N Engl J Med. 1999;341(23):1725–30. doi: 10.1056/NEJM199912023412303.CrossRefPubMedGoogle Scholar
  30. 30.
    Tang IY, Walzer N, Aggarwal N, Tzvetanov I, Cotler S, Benedetti E. Management of the kidney transplant patient with chronic hepatitis C infection. Int J Nephrol. 2011;2011:245823. doi: 10.4061/2011/245823.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Fabrizi F, Martin P, Dixit V, Bunnapradist S, Kanwal F, Dulai G. Post-transplant diabetes mellitus and HCV seropositive status after renal transplantation: Meta-analysis of clinical studies. Am J Transplant. 2005;5(10):2433–40. AJT1040 [pii].CrossRefPubMedGoogle Scholar
  32. 32.
    Campbell MS, Constantinescu S, Furth EE, Reddy KR, Bloom RD. Effects of hepatitis C-induced liver fibrosis on survival in kidney transplant candidates. Dig Dis Sci. 2007;52(10):2501–7. doi: 10.1007/s10620-006-9716-x.CrossRefPubMedGoogle Scholar
  33. 33.
    Mathurin P, Mouquet C, Poynard T, et al. Impact of hepatitis B and C virus on kidney transplantation outcome. Hepatology. 1999;29(1):257–63. S0270913999000348 [pii].CrossRefPubMedGoogle Scholar
  34. 34.
    Morales JM, Bloom R, Roth D. Kidney transplantation in the patient with hepatitis C virus infection. Contrib Nephrol. 2012;176:77–86. doi: 10.1159/000332385.CrossRefPubMedGoogle Scholar
  35. 35.
    Morales JM, Aguado JM. Hepatitis C and renal transplantation. Curr Opin Organ Transplant. 2012;17(6):609–15. doi: 10.1097/MOT.0b013e32835a2bac.CrossRefPubMedGoogle Scholar
  36. 36.
    Bloom RD, Sayer G, Fa K, Constantinescu S, Abt P, Reddy KR. Outcome of hepatitis C virus-infected kidney transplant candidates who remain on the waiting list. Am J Transplant. 2005;5(1):139–44. AJT652 [pii].CrossRefPubMedGoogle Scholar
  37. 37.
    Pereira BJ, Natov SN, Bouthot BA, et al. Effects of hepatitis C infection and renal transplantation on survival in end-stage renal disease. The New England Organ Bank Hepatitis C Study Group. Kidney Int. 1998;53(5):1374–81. doi: 10.1046/j.1523-1755.1998.00883.x.CrossRefPubMedGoogle Scholar
  38. 38.
    Espinosa M, Martin-Malo A, Alvarez de Lara MA, Aljama P. Risk of death and liver cirrhosis in anti-HCV-positive long-term haemodialysis patients. Nephrol Dial Transplant. 2001;16(8):1669–74.CrossRefPubMedGoogle Scholar
  39. 39.
    Roth D, Gaynor JJ, Reddy KR, et al. Effect of kidney transplantation on outcomes among patients with hepatitis C. J Am Soc Nephrol. 2011;22(6):1152–60. doi: 10.1681/ASN.2010060668.CrossRefPubMedPubMedCentralGoogle Scholar
  40. 40.
    Paramesh AS, Davis JY, Mallikarjun C, et al. Kidney transplantation alone in ESRD patients with hepatitis C cirrhosis. Transplantation. 2012;94(3):250–4. doi: 10.1097/TP.0b013e318255f890.CrossRefPubMedGoogle Scholar
  41. 41.
    Garcia-Tsao G, Parikh CR, Viola A. Acute kidney injury in cirrhosis. Hepatology. 2008;48(6):2064–77. doi: 10.1002/hep.22605.CrossRefPubMedGoogle Scholar
  42. 42.
    Angeli P, Sanyal A, Moller S, et al. Current limits and future challenges in the management of renal dysfunction in patients with cirrhosis: report from the International Club of Ascites. Liver Int. 2013;33(1):16–23. doi: 10.1111/j.1478-3231.2012.02807.x.CrossRefPubMedGoogle Scholar
  43. 43.
    Eason JD, Gonwa TA, Davis CL, Sung RS, Gerber D, Bloom RD. Proceedings of consensus conference on simultaneous liver kidney transplantation (SLK). Am J Transplant. 2008;8(11):2243–51. doi: 10.1111/j.1600-6143.2008.02416.x.CrossRefPubMedGoogle Scholar
  44. 44.
    Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders o pegylated interferon and ribavirin and treatment-naive patients: The COSMOS randomised study. Lancet. 2014;384(9956):1756–65. doi: 10.1016/S0140-6736(14)61036-9.CrossRefPubMedGoogle Scholar
  45. 45.
    Sorbera MA, Friedman ML, Cope R. New and emerging evidence on the use of second-generation direct acting antivirals for the treatment of hepatitis C virus in renal impairment. J Pharm Pract. 2016. pii: 0897190016632128. [Epub ahead of print].Google Scholar
  46. 46.
    Saxena V, Koraishy FM, Sise ME, et al. Safety and efficacy of sofosbuvir-containing regimens in hepatitis C infected patients with impaired renal function. Liver Int. 2016; doi: 10.1111/liv.13102.PubMedGoogle Scholar
  47. 47.
    Saxena V, Terrault NA. Treatment of hepatitis C infection in renal transplant recipients: the long wait is over. Am J Transplant. 2015; doi: 10.1111/ajt.13697.Google Scholar
  48. 48.
    Sawinski D, Kaur N, Ajeti A, et al. Successful treatment of hepatitis C in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2015; doi: 10.1111/ajt.13620.Google Scholar
  49. 49.
    Hussein NR, Sidiq Z, Saleem M. Successful treatment of hepatitis C virus genotype 4 in renal transplant recipients with direct-acting antiviral agents. Am J Transplant. 2016; doi: 10.1111/ajt.13767.PubMedGoogle Scholar

Copyright information

© Springer International Publishing AG 2017

Authors and Affiliations

  • Antonios Arvelakis
    • 1
  • Sander Florman
    • 1
  • Ron Shapiro
    • 1
  1. 1.Recanati/Miller Transplantation Institute, The Mount Sinai HospitalNew YorkUSA

Personalised recommendations